Pegus Cheryl

SEC source: 0001225208-26-005548 · doc4.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,770

F1 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $56.49 to $56.5009, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001225208-26-005111 · doc4.xml · derivative · entry 2

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,998

Underlying: Common Stock · 1,281 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · shares: Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.

F4 · derivative.exercise_date: Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.

F4 · derivative.expiration_date: Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.

SEC source: 0001225208-26-005111 · doc4.xml · derivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,717

Underlying: Common Stock · 3,800 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · shares: Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-26-003180 · doc4.xml · derivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,917

Underlying: Common Stock · 24 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Deferred stock units granted in lieu of 50% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $1,845.25, divided by the closing price of the common stock on the date of grant.

F2 · derivative.expiration_date: Deferred stock units granted in lieu of 50% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $1,845.25, divided by the closing price of the common stock on the date of grant.

SEC source: 0001104659-25-107876 · tm2530505-3_4seq1.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,740

F1 · kind: Grant of restricted stock which, subject to certain exceptions, will vest in full on November 4, 2026, the first anniversary of the grant date.

SEC source: 0001225208-25-004933 · doc4.xml · derivative · entry 2

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,893

Underlying: Common Stock · 605 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · shares: Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $62,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

F4 · derivative.exercise_date: Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $62,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

F4 · derivative.expiration_date: Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $62,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

SEC source: 0001225208-25-004933 · doc4.xml · derivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,288

Underlying: Common Stock · 2,081 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · shares: Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001415889-24-027938 · form4-11292024_101105.xml · nonDerivative · entry 2

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,992

F2 · kind: Grant of restricted stock which, subject to certain exceptions, will vest in full on November 26, 2025, the first anniversary of the grant date.

SEC source: 0001415889-24-027938 · form4-11292024_101105.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,496

F1 · kind: Grant of restricted stock which will vest in equal annual installments over five years.

SEC source: 0001225208-24-006566 · doc4.xml · derivative · entry 2

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,207

Underlying: Common Stock · 407 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · shares: Grant of deferred stock units in lieu of 25% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2025 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $30,737.50 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.exercise_date: Grant of deferred stock units in lieu of 25% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2025 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $30,737.50 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.expiration_date: Grant of deferred stock units in lieu of 25% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2025 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $30,737.50 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-24-006566 · doc4.xml · derivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,800

Underlying: Common Stock · 2,800 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · shares: Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2025 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $211,474 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F2 · derivative.exercise_date: Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2025 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $211,474 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F2 · derivative.expiration_date: Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2025 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $211,474 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001562180-21-004892 · primarydocument.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,825

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full upon the earlier of (i) July 8, 2022, and (ii) the next annual meeting of the Issuer's stockholders.

F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001562180-21-003745 · primarydocument.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,220

F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person.

F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0000899243-20-034496 · doc4.xml · nonDerivative · entry 3

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,775

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.80 to $56.655 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU respesents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0000899243-20-034496 · doc4.xml · derivative · entry 4

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,332

Underlying: Common Stock · 20,764 shares

Expires 2029-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 50% of this option vested and became exercisable on May 23, 2020, with the remainder vesting in three substantially equal installments thereafter.

SEC source: 0000899243-20-034496 · doc4.xml · nonDerivative · entry 2

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,190

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.75 to $56.18 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU respesents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0000899243-20-034496 · doc4.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,922

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU respesents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0000899243-20-019824 · doc4.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,158

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full upon the earlier of (i) July 8, 2021, and (ii) the next annual meeting of the Issuer's stockholders.

F2 · balance_after: A portion of these shares represent RSUs.

SEC source: 0001437749-20-009607 · rdgdoc.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,131

F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders.

SEC source: 0001437749-20-000148 · rdgdoc.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,459

F1 · shares: On December 31, 2019, the reporting person was granted 148 restricted stock units ("RSUs") in lieu of cash compensation of $10,000.00 pursuant to Tactile Systems Technology, Inc.'s Non-Employee Director Compensation Policy. The RSUs are 100% immediately vested and will be settled in Company's common stock upon the earlier of Dr. Pegus' separation from service from the Company's Board of Directors or a Change in Control as defined in the Policy.

F1 · price: On December 31, 2019, the reporting person was granted 148 restricted stock units ("RSUs") in lieu of cash compensation of $10,000.00 pursuant to Tactile Systems Technology, Inc.'s Non-Employee Director Compensation Policy. The RSUs are 100% immediately vested and will be settled in Company's common stock upon the earlier of Dr. Pegus' separation from service from the Company's Board of Directors or a Change in Control as defined in the Policy.

SEC source: 0000899243-19-029544 · doc4.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Echo Health Ventures LLC

Disclosed balance after: 1,681,439

F1 · kind: These shares were sold in a firm commitment underwritten public offering pursuant to an underwriting agreement dated as of December 12, 2019 by and among the Issuer, the several underwriters and the selling stockholders identified therein.

F2 · ownership.nature: Shares held directly by Echo Health Ventures LLC. Echo Health Ventures LLC is a joint venture between Cascadia Echo Holdings Company, LLC and Mosaic Health Solutions, LLC. Cascadia Echo Holdings LLC is a subsidiary of Cambia Health Solutions, LLC. The reporting person is the Chief Medical Officer and Senior Vice President of Cambia Health Solutions, LLC. The Reporting Person disclaims beneficial ownership over such shares, except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose.

SEC source: 0001437749-19-019478 · rdgdoc.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,311

F1 · shares: On September 30, 2019, the reporting person was granted 236 restricted stock units ("RSUs") in lieu of cash compensation of $10,000.00 pursuant to Tactile Systems Technology, Inc.'s Non-Employee Director Compensation Policy. The RSUs are 100% immediately vested and will be settled in Company's common stock upon the earlier of Dr. Pegus' separation from service from the Company's Board of Directors or a Change in Control as defined in the Policy.

F1 · price: On September 30, 2019, the reporting person was granted 236 restricted stock units ("RSUs") in lieu of cash compensation of $10,000.00 pursuant to Tactile Systems Technology, Inc.'s Non-Employee Director Compensation Policy. The RSUs are 100% immediately vested and will be settled in Company's common stock upon the earlier of Dr. Pegus' separation from service from the Company's Board of Directors or a Change in Control as defined in the Policy.

SEC source: 0000899243-19-020228 · doc4.xml · derivative · entry 3

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Echo Health Ventures LLC

Disclosed balance after: 0

Underlying: Common Stock · 2,462,128 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Senior B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-2.1973 basis. The Senior B Preferred Stock had no expiration date.

F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Senior B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-2.1973 basis. The Senior B Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Senior B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-2.1973 basis. The Senior B Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Senior B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-2.1973 basis. The Senior B Preferred Stock had no expiration date.

F2 · ownership.nature: Shares held directly by Echo Health Ventures LLC. Echo Health Ventures LLC is a joint venture between Cascadia Echo Holdings Company, LLC and Mosaic Health Solutions, LLC. Cascadia Echo Holdings LLC is a subsidiary of Cambia Health Solutions, LLC. The reporting person is the Chief Medical Officer and Senior Vice President of Cambia Health Solutions, LLC. The reporting person disclaims beneficial ownership over such shares, except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such shares.

SEC source: 0000899243-19-020228 · doc4.xml · nonDerivative · entry 2

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Echo Health Ventures LLC

Disclosed balance after: 2,181,439

F2 · ownership.nature: Shares held directly by Echo Health Ventures LLC. Echo Health Ventures LLC is a joint venture between Cascadia Echo Holdings Company, LLC and Mosaic Health Solutions, LLC. Cascadia Echo Holdings LLC is a subsidiary of Cambia Health Solutions, LLC. The reporting person is the Chief Medical Officer and Senior Vice President of Cambia Health Solutions, LLC. The reporting person disclaims beneficial ownership over such shares, except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such shares.

SEC source: 0000899243-19-020228 · doc4.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Echo Health Ventures LLC

Disclosed balance after: 2,462,128

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Senior B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-2.1973 basis. The Senior B Preferred Stock had no expiration date.

F2 · ownership.nature: Shares held directly by Echo Health Ventures LLC. Echo Health Ventures LLC is a joint venture between Cascadia Echo Holdings Company, LLC and Mosaic Health Solutions, LLC. Cascadia Echo Holdings LLC is a subsidiary of Cambia Health Solutions, LLC. The reporting person is the Chief Medical Officer and Senior Vice President of Cambia Health Solutions, LLC. The reporting person disclaims beneficial ownership over such shares, except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such shares.

SEC source: 0001437749-19-013358 · rdgdoc.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,075

F1 · shares: On June 28, 2019, the reporting person was granted 175 restricted stock units ("RSUs") in lieu of cash compensation of $10,000.00 pursuant to Tactile Systems Technology, Inc.'s Non-Employee Director Compensation Policy. The RSUs are 100% immediately vested and will be settled in Company's common stock upon the earlier of Dr. Pegus' separation from service from the Company's Board of Directors or a Change in Control as defined in the Policy.

F1 · price: On June 28, 2019, the reporting person was granted 175 restricted stock units ("RSUs") in lieu of cash compensation of $10,000.00 pursuant to Tactile Systems Technology, Inc.'s Non-Employee Director Compensation Policy. The RSUs are 100% immediately vested and will be settled in Company's common stock upon the earlier of Dr. Pegus' separation from service from the Company's Board of Directors or a Change in Control as defined in the Policy.

SEC source: 0001437749-19-009683 · rdgdoc.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,900

F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders.

SEC source: 0001437749-19-006396 · rdgdoc.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,746

F1 · shares: On March 29, 2019, the reporting person was granted 189 restricted stock units ("RSUs") in lieu of cash compensation of $10,000.00 pursuant to Tactile Systems Technology, Inc.'s Non-Employee Director Compensation Policy. The RSUs are 100% immediately vested and will be settled in Company's common stock upon the earlier of Dr. Pegus' separation from service from the Company's Board of Directors or a Change in Control as defined in the Plan.

F1 · price: On March 29, 2019, the reporting person was granted 189 restricted stock units ("RSUs") in lieu of cash compensation of $10,000.00 pursuant to Tactile Systems Technology, Inc.'s Non-Employee Director Compensation Policy. The RSUs are 100% immediately vested and will be settled in Company's common stock upon the earlier of Dr. Pegus' separation from service from the Company's Board of Directors or a Change in Control as defined in the Plan.

SEC source: 0001437749-18-009812 · rdgdoc.xml · derivative · entry 2

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,713

Underlying: Common Stock · 3,713 shares

Expires 2025-05-10

F2 · derivative.exercise_date: The options will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders.

SEC source: 0001437749-18-009812 · rdgdoc.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,557

F1 · shares: The restricted stock units will vest in full on the earlier of one year from the grant date or the date of the next year's annual meeting of the stockholders.

SEC source: 0001437749-18-007492 · rdgdoc.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: On April 20, 2018, these shares were purchased in a tender offer for all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") by Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC, pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement").

SEC source: 0001437749-17-020708 · rdgdoc.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,184

SEC source: 0001437749-17-014559 · rdgdoc.xml · derivative · entry 2

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,311

Underlying: Common Stock · 3,311 shares

Expires 2024-08-09

F2 · derivative.exercise_date: Stock Options will vest in full on the earlier of one year after the date of grant or the date of the next year's annual meeting of stockholders, provided the director remains a member of the board as of the vesting date.

SEC source: 0001437749-17-014559 · rdgdoc.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,184

F1 · shares: Restricted Stock Units (RSUs) will vest in full on the earlier of one year after the date of grant or the date of the next year's annual meeting of stockholders, provided the director remains a member of the board as of the vesting date. RSUs will settle in shares no later than March 15 of the calendar year following the date of vesting.

SEC source: 0001437749-17-009998 · rdgdoc.xml · nonDerivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,472

F1 · shares: This Restricted Stock Award vests in full six months from the date of grant.

F2 · balance_after: Total holdings include restricted stock awards.